FDA nod for Izervay, a new treatment for geographic atrophy

7 August 2023

The US Food and Drug Administration (FDA) approved Japanese drug major Astellas Pharma’s (TYO: 4503) Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) late Friday, sending the firm’s shares up more than 10% to 2,191 yen today.

Izervay, a new complement C5 inhibitor, is the only approved GA treatment with a statistically-significant reduction (p<0.01) in the rate of GA progression at the 12-month primary endpoint across two Phase III clinical trials, noted Astellas.

Astellas gained rights to the product through its recently completed buy of Iveric Bio for about $5.9 billon. Izervay is anticipated to be available in the USA in two-four weeks.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK